Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TristelTSNLF 95 12-1 Month Momentum % is 13.42% as of Aug. 31, 2026. GuruFocus rates TSNLF with a GF Score™ of 95/100 and a GF Value™ of $6.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 828 Medical Devices & Instruments companies, Tristel ranks better than 83.21% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-31), Tristel's 12-1 Month Momentum % is 13.42%.
The industry rank for Tristel's 12-1 Month Momentum % or its related term are showing as below:
TSNLF's 12-1 Month Momentum % is ranked better than 83.21% of 828
companies
in the Medical Devices & Instruments industry
Industry Median: -19.69
vs TSNLF: 13.42
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Tristel 12-1 Month Momentum % Related Terms
TSNLF vs ISRG, BDX, RMD: 12-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Tristel's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Tristel's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tristel (TSNLF) has a 12-1 Month Momentum % of 13.42% as of Aug. 31, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Tristel and its competitors. According to the industry distribution chart, Tristel ranks #139 out of 828 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Tristel's 12-1 Month Momentum % too high?
Tristel's current 12-1 Month Momentum % is 13.42%. Based on the distribution chart, Tristel ranks #139 out of 828 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tristel's 12-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #139 out of 828 companies for 12-1 Month Momentum %. This places Tristel in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Tristel and its competitors. Tristel's current 12-1 Month Momentum % is 13.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Fairly Valued. The stock's GF Value™ is $6.19, compared to a current price of $5.74 — trading 7.3% below its estimated fair value. The current 12-1 Month Momentum % is 13.42%. Tristel's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Tristel (TSNLF), the current 12-1 Month Momentum % is 13.42% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.74 is trading 7.3% below its estimated GF Value™ of $6.19.
GuruFocus considers Tristel to be Fairly Valued.
Key valuation signals for TSNLF:
12-1 Month Momentum %: 13.42%
GF Value™: $6.19 vs. price of $5.74 (7.3% below fair value)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
95GF Score
Get the complete analysis for TSNLF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
